N.sleven....Even if Amarin prevails in their case against Hikma, Hikma will then institute lengthy appeals. It is true,however, that Amarin's winning the case against Hikma may make other generic cos. think twice against infringing on Amarin's CVD patent.
Amarin's main opportunity for the near term revolves around the approval of Lr-ET-EPA by the patent office and then by the FDA.
Market Data 
Markets 
AI
